Loading...

TruStain FcX™ PLUS (anti-mouse CD16/32) Antibody

Pricing & Availability
Clone
S17011E (See other available formats)
Regulatory Status
RUO
Other Names
CD16, CD32
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
TruStain_FcX_Plus_CD16-CD32_Antibody_122018_updated.png
BALB/c splenocytes were incubated with TruStain FcX™ PLUS (clone S17011E, 0.25µg/106 cells, filled histogram) or TruStain FcX™ (clone 93, 1µg/106 cells, red line histogram) to block the Fc receptors, or were left untreated (black line histogram); then stained with CD90.2 (Thy-1.2, clone 53-2.1) FITC. Note the high background in the untreated cells and the bigger reduction in the background staining when the cells were incubated with TruStain FcX™ Plus compared to TruStain FcX™.
  • TruStain_FcX_Plus_CD16-CD32_Antibody_122018_updated.png
    BALB/c splenocytes were incubated with TruStain FcX™ PLUS (clone S17011E, 0.25µg/106 cells, filled histogram) or TruStain FcX™ (clone 93, 1µg/106 cells, red line histogram) to block the Fc receptors, or were left untreated (black line histogram); then stained with CD90.2 (Thy-1.2, clone 53-2.1) FITC. Note the high background in the untreated cells and the bigger reduction in the background staining when the cells were incubated with TruStain FcX™ Plus compared to TruStain FcX™.
Cat # Size Price Quantity Check Availability Save
156603 50 µg 65 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
156604 500 µg 276 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD16 is the low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses. TruStain FcX™ PLUS is specific to the common epitope of CD16/CD32. It is useful for blocking non-specific binding of immunoglobulin to the Fc receptors and is more effective than TruStain FcX™.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Purity
The antibody was purified by affinity chromatography.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration
0.5 mg/ml
Storage & Handling
The CD16/32 antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Recommended Usage

For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with TruStain FcX™ PLUS for 5-10 minutes, on ice, at 0.25 µg per 106 cells in a volume of 100 µl, prior to immunostaining. It is not necessary to wash the cells between the blocking and immunostaining steps.

Application Notes

Clone S17011E blocks both clone 93 and 2.4G2 also raised against mouse CD16/32

Product Citations
  1. Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed
  2. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  3. Fu R, et al. 2020. Sci Rep. 10:1455. PubMed
  4. Westphal A, et al. 2017. J Exp Med. 214:227. PubMed
  5. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  6. Badgujar DC, et al. 2020. PLoS Pathog. 16:e1009016. PubMed
  7. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  8. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  9. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  10. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  11. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  12. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  13. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  14. Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed
  15. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  16. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  17. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  18. Zhou J, et al. 2021. J Immunother Cancer. 9:. PubMed
  19. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  20. Wang Y, et al. 2021. Nature. 599:308. PubMed
  21. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  22. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  23. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  24. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  25. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  26. Ejima R, et al. 2021. Nutrients. 13:. PubMed
  27. Oya Y, et al. 2021. Front Immunol. 12:779709. PubMed
  28. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  29. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  30. Galani IE, et al. 2022. STAR Protoc. 3:101151. PubMed
  31. Thomas AM, et al. 2022. J Neuroinflammation. 19:130. PubMed
  32. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  33. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  34. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  35. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  36. Ikeda S, et al. 2022. Sci Rep. 12:11564. PubMed
  37. Thinard R, et al. 2022. Pharmaceutics. 14:. PubMed
  38. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  39. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  40. Music A, et al. 2022. Front Cell Dev Biol. 10:987148. PubMed
  41. Matsuda A, et al. 2020. J Appl Toxicol. 40:706. PubMed
  42. So EY, et al. 2021. Am J Physiol Cell Physiol. 321:C569. PubMed
  43. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  44. Driscoll J, et al. 2021. Curr Protoc. 1:e249. PubMed
  45. Montel-Hagen A, et al. 2022. Curr Protoc. 2:e403. PubMed
  46. Wang JC, et al. 2022. Elife. 11:. PubMed
  47. Chen AF, et al. 2022. Nat Methods. 19:547. PubMed
  48. Dong L, et al. 2022. Cells. 11:. PubMed
  49. Chen S, et al. 2022. iScience. 25:105176. PubMed
  50. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  51. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  52. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  53. Chen X, et al. 2022. J Appl Oral Sci. 30:e20220316. PubMed
  54. Toomer G, et al. 2022. Viruses. 14:. PubMed
  55. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  56. Bruno MEC, et al. 2022. J Cell Physiol. 237:706. PubMed
  57. Sweeney-Ambros AR, et al. 2022. J Orthop Res. 40:2843. PubMed
  58. Sugimoto M, et al. 2022. DNA Res. 29: . PubMed
  59. Wu J, et al. 2023. Bioact Mater. 20:259. PubMed
  60. Campisi L, et al. 2022. Nature. 606:945. PubMed
  61. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  62. Li L, et al. 2022. J Exp Med. 219: . PubMed
  63. Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed
  64. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  65. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  66. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  67. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  68. Cagle LA, et al. 2023. Front Physiol. 13:1059686. PubMed
  69. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  70. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
  71. Chun J, et al. 2023. Cancers (Basel). 15: . PubMed
  72. Miller CL, et al. 2022. Cell Chem Biol. 29:451. PubMed
  73. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  74. Gonzalez C, et al. 2022. Life Sci. 309:121003. PubMed
  75. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  76. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  77. Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed
  78. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  79. Sang H, et al. 2023. Adv Clin Exp Med. 32:551. PubMed
  80. Zyla-Jackson K, et al. 2023. Front Neurol. 14:1113954. PubMed
  81. Chen Y, et al. 2023. J Nanobiotechnology. 21:98. PubMed
  82. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  83. Zhou Y, et al. 2023. NPJ Regen Med. 8:23. PubMed
  84. Barisas DAG, et al. 2023. PLoS Biol. 21:e3001746. PubMed
  85. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  86. Lin W, et al. 2023. Commun Biol. 6:447. PubMed
  87. Miyake K, et al. 2023. Nat Commun. 14:2694. PubMed
  88. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  89. Arora S, et al. 2023. PLoS One. 18:e0286211. PubMed
  90. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
RRID
AB_2783137 (BioLegend Cat. No. 156603)
AB_2783138 (BioLegend Cat. No. 156604)

Antigen Details

Structure
Ig superfamily, 40-60 kD
Distribution

B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells

Ligand/Receptor
IgG
Cell Type
B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area
Immunology
Molecular Family
CD Molecules, Fc Receptors
Gene ID
14130 View all products for this Gene ID 14131 View all products for this Gene ID
UniProt
View information about CD16/32 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 01.22.2019

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account